Verde AgriTech Granted Patent for Advanced Fertilizer Production Technology Combining Glauconitic Siltstone and Beneficial Microorganisms SINGAPORE, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd. (TSX: NPK | OTCQX: VNPKF) ("Verde” or the “Company”), a specialty multi-nutrient potassium fertilizer innovator offering tailored solutions to support sustainable farming practices, is pleased to announce that its subsidiary Verde Fertilizantes LTDA has been granted a Brazilian patent (No. BR 10 2021 015788 7 - PROCESSO DE PRODUÇÃO DE FERTILIZANTE MINERAL EMPREGANDO INOCULAÇÃO COM ADITIVO...
Voyager to Present at Upcoming Investor Conferences LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference: Fireside chat at 4:00 p.m. ET on Tuesday, September 2, 2025, in Boston, MA, during which the company plans to highlight preclinical data supporting its non-viral delivery platform leveraging novel receptor-b...
Verde Announces Q2 2025 Earnings Results SINGAPORE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) announces its financial results for the period ended June 30, 2025 (“Q2 2025”). All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in Q2 2025: C$1.00 = R$4.08. Q2 2025 HIGHLIGHTS Operational and Financial Highlights Verde's sales volume in Q2 2025 was 80,354 tons; a 6% reduction compared to Q2 2024, which generated $4.8 million in revenue during the quarter.Gross margin excluding freight was 58% during the quar...
Voyager Reports Second Quarter 2025 Financial and Operating Results - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2025 financial and op...
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now includes clinical-stage anti-tau antibody VY7523 as well as gene therapies targeting tau, amyloid, and APOE - LEXINGTON, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a...
Verde announces results of the 2025 Annual General Meeting of shareholders SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd. (TSX: “NPK”) ("Verde” or the “Company”) held its Annual General Meeting of shareholders (the “Meeting”) on Monday, June 30, 2025, at 300 Prof. Antônio Aleixo, Lourdes Belo Horizonte, Minas Gerais Brazil, and is pleased to announce that its shareholders approved all items put before them. The results were as follows: Item Voted UponVoting Results Votes ForVotes AgainstAdoption of the 2024 Audited Statement of Accounts10,835,601(98.971%)112,679(...
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and...
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineer...
Verde Announces Q1 2025 Results (All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in Q1 2025: C$1.00 = R$3.93) SINGAPORE, May 15, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) announces its financial results for the period ended March 31, 2025 (“Q1 2025”). As previously disclosed on March 28, 20251, product deliveries for the first half of 2025 were significantly impacted by the severe crisis in the Brazilian agricultural sector, which led to the insolvency of some of the country’s largest agricultural input su...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.